分享即关怀:一种网络协作方法,用于识别和解决在白血病和淋巴瘤青少年和年轻成人中获得临床试验的障碍。

IF 2.9 3区 教育学 Q1 EDUCATION, SCIENTIFIC DISCIPLINES Hematology. American Society of Hematology. Education Program Pub Date : 2024-12-06 DOI:10.1182/hematology.2024000526
Caroline Hesko, Jessica Heath, Michael E Roth, Nupur Mittal
{"title":"分享即关怀:一种网络协作方法,用于识别和解决在白血病和淋巴瘤青少年和年轻成人中获得临床试验的障碍。","authors":"Caroline Hesko, Jessica Heath, Michael E Roth, Nupur Mittal","doi":"10.1182/hematology.2024000526","DOIUrl":null,"url":null,"abstract":"<p><p>Leukemia and lymphoma are 2 common hematologic cancers in adolescents and young adults (AYAs, age 15-39 years at diagnosis); however, this population has historically had lower clinical trial enrollment and less dramatic improvements in overall survival compared to other age populations. Several unique challenges to delivering care to this population have affected drug development, clinical trial availability, accessibility, and acceptance, all of which impact clinical trial enrollment. Recently, several national and institutional collaborative approaches have been utilized to improve trial availability and accessibility for AYAs with hematologic malignancies. In this review, we discuss the known barriers to cancer clinical trial enrollment and potential approaches and solutions to improve enrollment for AYAs with leukemia and lymphoma on clinical trials.</p>","PeriodicalId":12973,"journal":{"name":"Hematology. American Society of Hematology. Education Program","volume":"2024 1","pages":"27-33"},"PeriodicalIF":2.9000,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665597/pdf/","citationCount":"0","resultStr":"{\"title\":\"Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma.\",\"authors\":\"Caroline Hesko, Jessica Heath, Michael E Roth, Nupur Mittal\",\"doi\":\"10.1182/hematology.2024000526\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Leukemia and lymphoma are 2 common hematologic cancers in adolescents and young adults (AYAs, age 15-39 years at diagnosis); however, this population has historically had lower clinical trial enrollment and less dramatic improvements in overall survival compared to other age populations. Several unique challenges to delivering care to this population have affected drug development, clinical trial availability, accessibility, and acceptance, all of which impact clinical trial enrollment. Recently, several national and institutional collaborative approaches have been utilized to improve trial availability and accessibility for AYAs with hematologic malignancies. In this review, we discuss the known barriers to cancer clinical trial enrollment and potential approaches and solutions to improve enrollment for AYAs with leukemia and lymphoma on clinical trials.</p>\",\"PeriodicalId\":12973,\"journal\":{\"name\":\"Hematology. American Society of Hematology. Education Program\",\"volume\":\"2024 1\",\"pages\":\"27-33\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-12-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665597/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology. American Society of Hematology. Education Program\",\"FirstCategoryId\":\"95\",\"ListUrlMain\":\"https://doi.org/10.1182/hematology.2024000526\",\"RegionNum\":3,\"RegionCategory\":\"教育学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"EDUCATION, SCIENTIFIC DISCIPLINES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology. American Society of Hematology. Education Program","FirstCategoryId":"95","ListUrlMain":"https://doi.org/10.1182/hematology.2024000526","RegionNum":3,"RegionCategory":"教育学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"EDUCATION, SCIENTIFIC DISCIPLINES","Score":null,"Total":0}
引用次数: 0

摘要

白血病和淋巴瘤是两种常见于青少年和年轻人的血液学癌症(AYAs,诊断时年龄为15-39岁);然而,与其他年龄人群相比,这一人群在历史上的临床试验入组率较低,总体生存率的改善也不明显。向这一人群提供护理的几个独特挑战影响了药物开发、临床试验的可获得性、可及性和可接受性,所有这些都影响了临床试验的入组。最近,一些国家和机构合作的方法已被用于改善血液恶性肿瘤的AYAs的试验可获得性和可及性。在这篇综述中,我们讨论了癌症临床试验入组的已知障碍,以及提高白血病和淋巴瘤AYAs临床试验入组的潜在方法和解决方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma.

Leukemia and lymphoma are 2 common hematologic cancers in adolescents and young adults (AYAs, age 15-39 years at diagnosis); however, this population has historically had lower clinical trial enrollment and less dramatic improvements in overall survival compared to other age populations. Several unique challenges to delivering care to this population have affected drug development, clinical trial availability, accessibility, and acceptance, all of which impact clinical trial enrollment. Recently, several national and institutional collaborative approaches have been utilized to improve trial availability and accessibility for AYAs with hematologic malignancies. In this review, we discuss the known barriers to cancer clinical trial enrollment and potential approaches and solutions to improve enrollment for AYAs with leukemia and lymphoma on clinical trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hematology. American Society of Hematology. Education Program
Hematology. American Society of Hematology. Education Program EDUCATION, SCIENTIFIC DISCIPLINES-HEMATOLOGY
CiteScore
4.70
自引率
3.30%
发文量
0
期刊介绍: Hematology, the ASH Education Program, is published annually by the American Society of Hematology (ASH) in one volume per year.
期刊最新文献
Novel conditioning and prophylaxis regimens for relapse prevention. On the horizon: upcoming new agents for the management of ITP. Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies. The POD24 challenge: where do we go from here for early progressors? Givosiran: a targeted treatment for acute intermittent porphyria.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1